Epigenetics emerges powerfully as a clinical tool

GSTP1 and MGMT: These are case examples for epigenetic profiling in diagnosis and prognosis.

A study coordinated by Manel Esteller, published in Nature Reviews Genetics, highlights the success of this area of research to predict the behavior and weaknesses of tumors.

The research team led by Manel Esteller, director of the Cancer Epigenetics and Biology Program at the Bellvitge Biomedical Research Institute (IDIBELL), professor of genetics at the University of Barcelona and ICREA researcher, has updated the latest findings in applied epigenetics in a review paper published in Nature Reviews Genetics.

There is a growing need for better biomarkers that allow early detection of human diseases, especially cancer. The markers can improve primary prevention, diagnosis and prognosis of disease. Furthermore, it is possible to predict which may be more effective treatment according to patient characteristics, which is known by the name of personalized medicine.

Genetic tests complementary to traditional methods have been used to improve the approach to various diseases, but in the last ten years Epigenetics has hardly emerged to help solve these clinical situations, as highlighted by the article. Epigenetics is the discipline for the study of the in our genetic material and the same . The most known epigenetic mark is the addition of a to the DNA.

The study notes that the last decade two tests based on the methylation of two genes, MGMT and GSTP1, have been proved vital in predicting sensitive to the temozolomide drug and in distinguishing prostate cancer compared benign growth, respectively. Dr. Esteller points out that "the most exciting thing is that they are currently being identified new epigenetic for predicting the performance and weaknesses of tumours at a fast pace." In this sense, the coordinator of the study cites the recent identification of epigenetic alterations in predictive genes as response to new generation drugs in leukaemia and the fact that obtaining a "picture" of the DNA methylation pattern can expose unknown tumours that previously had a very poor prognosis.

More information: Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nature Reviews Genetics, September 4, 2012.

add to favorites email to friend print save as pdf

Related Stories

Researchers complete the first epigenome in Europe

May 30, 2012

A study led by Manel Esteller, director of the Epigenetics and Cancer Biology Program at the Bellvitge Biomedical Research Institute (IDIBELL), professor of genetics at the University of Barcelona and ICREA researcher, has ...

Why cancer cells change their appearance?

Sep 02, 2011

Like snakes, tumour cells shed their skin. Cancer is not a static disease but during its development the disease accumulates changes to evade natural defences adapting to new environmental circumstances, protecting against ...

Recommended for you

Schizophrenia's genetic architecture revealed (w/ Video)

21 hours ago

Queensland scientists are closer to effective treatments for schizophrenia after uncovering dozens of sites across the human genome that are strongly associated with a genetic predisposition to schizophrenia.

Mysterious esophagus disease is autoimmune after all

Jul 22, 2014

(Medical Xpress)—Achalasia is a rare disease – it affects 1 in 100,000 people – characterized by a loss of nerve cells in the esophageal wall. While its cause remains unknown, a new study by a team of researchers at ...

Diagnostic criteria for Christianson Syndrome

Jul 21, 2014

Because the severe autism-like condition Christianson Syndrome was only first reported in 1999 and some symptoms take more than a decade to appear, families and doctors urgently need fundamental information ...

User comments